Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
Income from Continuing Operations
Jiangsu Hengrui Pharmaceuticals Co Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income from Continuing Operations
¥4.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
1%
|
CAGR 10-Years
13%
|
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
Income from Continuing Operations
¥6.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income from Continuing Operations
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Income from Continuing Operations
¥3.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income from Continuing Operations
¥4.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Income from Continuing Operations
-¥780.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
4.4B
CNY
Based on the financial report for Mar 31, 2024, Jiangsu Hengrui Pharmaceuticals Co Ltd's Income from Continuing Operations amounts to 4.4B CNY.
What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
13%
Over the last year, the Income from Continuing Operations growth was 15%. The average annual Income from Continuing Operations growth rates for Jiangsu Hengrui Pharmaceuticals Co Ltd have been -12% over the past three years , 1% over the past five years , and 13% over the past ten years .